<DOC>
	<DOCNO>NCT00016380</DOCNO>
	<brief_summary>RATIONALE : Antiemetic drug may help reduce prevent vomit patient treat radiation therapy . It yet know ondansetron effective without dexamethasone prevent vomit cause radiation therapy . PURPOSE : This randomized phase III trial compare well ondansetron work without dexamethasone prevent vomit patient cancer receive radiation therapy upper abdomen .</brief_summary>
	<brief_title>Ondansetron With Without Dexamethasone Prevent Vomiting Patients Receiving Radiation Therapy Upper Abdomen</brief_title>
	<detailed_description>OBJECTIVES : - Compare effectiveness ondansetron without dexamethasone prophylaxis radiation-induced emesis nausea patient receive upper abdominal radiotherapy . - Compare toxicity regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord radiotherapy field description ( whole abdomen pelvis vs partial abdomen pelvis vs partial abdomen ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral ondansetron twice daily oral dexamethasone daily 5-7 day concurrently first 5 fraction radiotherapy . - Arm II : Patients receive oral ondansetron twice daily oral placebo daily 5-7 day concurrently first 5 fraction radiotherapy . Treatment continue arm absence disease progression unacceptable toxicity . Quality life assess baseline , prior start radiotherapy 5 day since randomization , prior 5th 15th fraction radiotherapy , 1 month completion radiotherapy . Patients follow 1 month . PROJECTED ACCRUAL : A total 100-200 patient ( 50-100 per arm ) accrue study .</detailed_description>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cancer patient schedule receive radiotherapy within next 3 week Total dose least 2,000 cGy deliver least 15 fraction 1 fraction per day , 5 day per week Treatment field include area least 80 cm2 anterior/posterior direction encompass upper abdomen At risk develop radiationinduced emesis No emesis ( retch and/or vomit ) nausea severity great 2 within past week PATIENT CHARACTERISTICS : Age : 16 Performance status : ECOG 03 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : No jaundice No moderate severe hepatic dysfunction Renal : Not specify Gastrointestinal : No active peptic ulcer No lactose intolerance Other : No concurrent condition illness contraindicates corticosteroid , serotonin antagonist , prochlorperazine ( e.g. , diabetes mellitus ) No prior unusual allergic reaction serotonin antagonist ( ondansetron , dolasetron , granisetron ) , corticosteroid , prochlorperazine No condition would preclude accessibility treatment followup Able willing complete diary quality life questionnaires either English French Able swallow PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 1 week since prior cytotoxic therapy No concurrent cytotoxic therapy Endocrine therapy : No concurrent corticosteroids topical inhaled preparation Radiotherapy : See Disease Characteristics At least 1 week since prior radiotherapy No concurrent cranial radiotherapy Surgery : Not specify Other : At least 2 day since prior medication antiemetic intent</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>nausea vomit</keyword>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage I gastric cancer</keyword>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>stage IA cervical cancer</keyword>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>localize gastrointestinal carcinoid tumor</keyword>
	<keyword>regional gastrointestinal carcinoid tumor</keyword>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>localize resectable adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>small intestine adenocarcinoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>small intestine leiomyosarcoma</keyword>
	<keyword>localize gallbladder cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>localize extrahepatic bile duct cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>recurrent small intestine cancer</keyword>
	<keyword>testicular seminoma</keyword>
	<keyword>carcinoma appendix</keyword>
	<keyword>quality life</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>